Last-resort radiation treatment offers hope for rare childhood and adult cancers
NCT ID NCT01850888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gave a radioactive drug called 131I-MIBG to 15 people with advanced nerve tumors (neuroblastoma or pheochromocytoma) that had stopped responding to standard treatments. The goal was to see if it could ease symptoms and shrink tumors, while tracking side effects. Participants received different doses based on their health and stem cell availability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States